Clinical Trial Detail

NCT ID NCT02352844
Title Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Advanced Solid Tumor

Therapies

Everolimus

Age Groups: adult

Additional content available in CKB BOOST